Journal
ONCOTARGET
Volume 8, Issue 22, Pages 36845-36856Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.15982
Keywords
prognostic; progesterone receptor; ovarian cancer; meta-analysis
Categories
Funding
- Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents
Ask authors/readers for more resources
Objective: While a prognosis value of progesterone receptor (PR) in ovarian cancer has been reported in some publications, controversial data were presented by different reports. In order to address the disagreement of progesterone receptor in ovarian cancer survival, we conducted this meta-analysis. Methods: Relevant articles on progesterone receptor and ovarian cancer prognosis were identified via a thorough search of PubMed, Embase and Cochrane Central. Hazard ratios (HR) and 95% confidence interval (CI) were extracted from studies on overall survival (OS) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS). Result: A total of 28 eligible studies containing 5685 patients were collected for analysis. It was found that progesterone receptor positivity was significantly associated with favorable overall survival (OS) (HR = 0.86, 95% CI = 0.78 to 0.95, P = 0.002) and disease-free survival (DFS)/progress-free survival (PFS)/recurrence-free survival (RFS) (HR = 0.75, 95% CI = 0.61 to 0.93, P = 0.008) of ovarian cancer patients. Subgroup analysis showed that progesterone receptor expression was associated with a favorable prognosis of unclassified ovarian cancer, European origin, and immunohistochemical detection method. Conclusion: Progesterone receptor expression can be used as a favorable prognostic predictor in ovarian cancer managements.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available